Medisca and dsm–firmenich Collaborate to Broaden U.S. Access to Pharmaceutical-Grade Vitamin APIs for Compounding Pharmacies
Medisca, a global provider of personalized pharmaceutical solutions and compounding technologies, has announced a strategic partnership with dsm–firmenich, an international manufacturer of pharmaceutical ingredients and nutritional solutions serving regulated healthcare markets worldwide. The collaboration is designed to expand access to pharmaceutical-grade vitamin active pharmaceutical ingredients (APIs) for compounding professionals throughout the United States.
Under the agreement, Medisca will distribute a portfolio of pharmaceutical-grade vitamin APIs manufactured by dsm–firmenich, making these ingredients available to pharmacies, compounding professionals, and 503B outsourcing facilities across the U.S. market. The ingredients are produced within European current Good Manufacturing Practice (cGMP) environments and supported by extensive quality systems, regulatory documentation, and manufacturing controls intended to meet the evolving standards of modern pharmaceutical compounding.
The partnership reflects growing demand within the compounding industry for high-quality pharmaceutical ingredients that can support increasingly regulated and complex healthcare environments. As personalized medicine and customized therapeutic formulations continue gaining importance in patient care, compounding pharmacies are under increasing pressure to ensure ingredient consistency, traceability, quality assurance, and regulatory compliance.
By combining Medisca’s expertise in serving compounding professionals with dsm–firmenich’s global manufacturing infrastructure and pharmaceutical ingredient capabilities, the companies aim to strengthen supply reliability while helping healthcare providers maintain confidence in the materials used to prepare personalized medications.
The collaboration also represents part of a broader industry movement toward strengthening pharmaceutical supply chains and improving access to trusted ingredient sources. In recent years, pharmacies and outsourcing facilities have placed greater emphasis on sourcing APIs from manufacturers operating under rigorous quality standards, particularly as regulatory scrutiny surrounding compounding practices continues to increase.
According to the companies, the partnership is intended to support compounding professionals by providing ingredient solutions backed by established manufacturing processes, robust documentation practices, and long-term supply continuity. The companies emphasized that ingredient sourcing has become a foundational element of operational trust and product quality in the compounding sector.
The pharmaceutical compounding industry plays a critical role in healthcare by enabling customized medications tailored to individual patient needs. Compounded preparations are commonly used when commercially available products do not meet specific patient requirements, such as dosage modifications, allergen-free formulations, alternative delivery methods, or combinations of ingredients not otherwise available through standard pharmaceutical products.
As healthcare systems increasingly focus on personalized medicine, demand for customized therapies has continued to expand across multiple therapeutic areas. This growth has also led to heightened expectations around manufacturing standards, documentation practices, ingredient traceability, and operational consistency for compounding providers.
Within the United States, both traditional compounding pharmacies and federally regulated 503B outsourcing facilities have faced growing regulatory oversight intended to strengthen quality standards and reduce supply chain risks. These organizations increasingly require reliable ingredient partners capable of supporting high-volume production environments while maintaining compliance with evolving regulatory expectations.
The partnership between Medisca and dsm–firmenich is specifically structured to address these needs by creating an established commercial and technical distribution model for pharmaceutical-grade vitamin APIs. The companies stated that the arrangement is designed to support regulated compounding use while ensuring long-term continuity for pharmacies and outsourcing facilities.
Peng Li, Vice President of Strategic Partnerships at Medisca, described the collaboration as an important step in strengthening ingredient sourcing options available to the compounding industry. He emphasized that reliable sourcing is essential to maintaining both operational confidence and long-term success within pharmaceutical compounding.
According to Li, partnering with a globally recognized manufacturing organization such as dsm–firmenich allows Medisca to further expand the range of high-quality ingredient solutions available through its network. He stated that the addition of pharmaceutical-grade vitamin APIs into the Medisca ecosystem helps support the evolving needs of compounding professionals while preserving the operational workflows and customer relationships that healthcare providers depend upon.
Li also noted that the partnership aligns with Medisca’s broader mission of supporting innovation and quality across personalized medicine and pharmaceutical compounding practices. By improving access to pharmaceutical-grade ingredients manufactured under stringent cGMP standards, the company aims to help customers maintain greater consistency and reliability in patient care.
Jennifer McManus, Senior Sales Director at dsm–firmenich, stated that the partnership represents a meaningful opportunity to expand access to high-quality vitamin APIs within the U.S. compounding market. She explained that combining dsm–firmenich’s global manufacturing expertise and cGMP-focused production capabilities with Medisca’s deep understanding of the compounding sector creates a stronger support framework for pharmacies and outsourcing facilities.
McManus added that the collaboration is expected to improve supply reliability while enabling customers to operate with greater confidence, consistency, and quality assurance in patient care activities. She highlighted that dependable access to pharmaceutical-grade ingredients remains a critical component of maintaining trust across regulated healthcare environments.
The initial portfolio being introduced through the partnership includes pharmaceutical-grade vitamin APIs manufactured according to European cGMP standards. These manufacturing standards are designed to ensure high levels of product consistency, quality control, contamination prevention, and regulatory compliance throughout production processes.
European cGMP manufacturing environments are widely recognized within the pharmaceutical industry for adhering to strict operational guidelines related to facility management, process validation, quality assurance, and documentation systems. Access to ingredients produced under these standards can help compounding organizations strengthen compliance efforts and improve confidence in ingredient integrity.
The companies also indicated that additional products are expected to be introduced over time as the partnership expands. Medisca customers in the United States will be able to access ordering information, pricing details, and lead-time guidance through the company’s sales representatives.
The agreement comes amid broader efforts across the pharmaceutical industry to strengthen domestic access to reliable and traceable ingredient supply chains. Supply disruptions experienced in recent years have highlighted vulnerabilities in global pharmaceutical sourcing networks, increasing demand for stable partnerships capable of ensuring consistent ingredient availability.
For compounding pharmacies and outsourcing facilities, disruptions in API supply can create operational challenges that directly affect patient access to customized medications. Reliable sourcing partnerships are therefore becoming increasingly important as providers seek to maintain uninterrupted patient care while complying with evolving regulatory standards.
In addition to supply continuity, quality documentation has become an increasingly important factor in compounding operations. Pharmacies and outsourcing facilities often require detailed certificates of analysis, stability data, regulatory documentation, and manufacturing records to support internal quality systems and external compliance requirements.
The Medisca and dsm–firmenich partnership aims to address these operational needs by offering ingredients supported by established documentation standards and technical support infrastructure. The companies believe this approach will help customers scale operations more effectively while maintaining confidence in ingredient quality and traceability.
The collaboration also underscores the growing convergence between pharmaceutical manufacturing standards and personalized medicine practices. As compounding continues evolving into a more sophisticated and highly regulated segment of healthcare delivery, partnerships focused on quality, consistency, and compliance are expected to become increasingly important across the industry.
By leveraging dsm–firmenich’s manufacturing capabilities and Medisca’s established relationships within the compounding community, the companies aim to create a stronger foundation for pharmacies and outsourcing facilities navigating the complexities of modern personalized medicine.
With additional product introductions planned for the future, the partnership is expected to further expand ingredient options available to U.S. compounding professionals while reinforcing operational reliability and quality-focused practices throughout the sector.
About dsm–firmenich
As innovators in nutrition, health, and beauty, dsm–firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With its comprehensive range of solutions, natural and renewable ingredients, and renowned science and technology capabilities, the company creates what is essential for life, desirable for consumers, and more sustainable for people and the planet. dsm–firmenich is a Swiss company with dual headquarters in Kaiseraugst, Switzerland and Maastricht, Netherlands, listed on Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, dsm–firmenich brings progress to life every day, everywhere, for billions of people. www.dsm-firmenich.com
About Medical
Founded in 1989, Medisca is a leader in personalized medicine and pharmaceutical supply chain solutions, with a vast portfolio of over 2,000 products complemented by a library of 10,000+ proprietary and customized medication formulas, expertise and services in pharmaceutical compounding, continuing healthcare education, and analytical testing. Providing finely-tuned solutions to diverse wellness sectors in numerous markets globally, Medisca is bridging the gaps in healthcare and empowering personalized wellness for all.
